Avicanna Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.304
- Today's High:
- $0.304
- Open Price:
- $0.304
- 52W Low:
- $0.117
- 52W High:
- $0.41
- Prev. Close:
- $0.304
- Volume:
- 0
Company Statistics
- Market Cap.:
- $19.97 million
- Book Value:
- 0.014
- Revenue TTM:
- $4.18 million
- Operating Margin TTM:
- -289.96%
- Gross Profit TTM:
- $1.12 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -34.32%
- Return on Equity TTM:
- -213.2%
Company Profile
Avicanna Inc had its IPO on under the ticker symbol AVCNF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Avicanna Inc has a staff strength of 80 employees.
Stock update
Shares of Avicanna Inc opened at $0.3 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.3 - $0.3, and closed at $0.3.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Avicanna Inc have slipped by -0.65%.
Avicanna Inc's Key Ratios
Avicanna Inc has a market cap of $19.97 million, indicating a price to book ratio of 9.3215 and a price to sales ratio of 4.511.
In the last 12-months Avicanna Inc’s revenue was $4.18 million with a gross profit of $1.12 million and an EBITDA of $-11625777. The EBITDA ratio measures Avicanna Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Avicanna Inc’s operating margin was -289.96% while its return on assets stood at -34.32% with a return of equity of -213.2%.
In Q1, Avicanna Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 12.7%.
Avicanna Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.19 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Avicanna Inc’s profitability.
Avicanna Inc stock is trading at a EV to sales ratio of 4.8803 and a EV to EBITDA ratio of -1.4638. Its price to sales ratio in the trailing 12-months stood at 4.511.
Avicanna Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $17.85 million
- Total Liabilities
- $10.38 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $16447
- Dividend Payout Ratio
- 0%
Avicanna Inc ended 2024 with $17.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $17.85 million while shareholder equity stood at $1.17 million.
Avicanna Inc ended 2024 with $0 in deferred long-term liabilities, $10.38 million in other current liabilities, in common stock, $-93251368.00 in retained earnings and $0 in goodwill. Its cash balance stood at $221875.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $137891.00.
Avicanna Inc’s total current assets stands at $7.00 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.97 million compared to accounts payable of $4.69 million and inventory worth $3.44 million.
In 2024, Avicanna Inc's operating cash flow was $0 while its capital expenditure stood at $16447.
Comparatively, Avicanna Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.3
- 52-Week High
- $0.41
- 52-Week Low
- $0.117
- Analyst Target Price
- $
Avicanna Inc stock is currently trading at $0.3 per share. It touched a 52-week high of $0.41 and a 52-week low of $0.41. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.24 and 200-day moving average was $0.27 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 2073.7% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Avicanna Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen’sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.